Phase II dose-finding and interception study of linvoseltamab in patients with high-risk monoclonal gammopathy of undetermined extent or non-high-risk asymptomatic multiple myeloma.
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: ICON CLINICAL RESEARCH LTD
- Phase: II
- Execution start: 22/08/2024
- End of execution: 26/06/2032
- IP: MARIA ESTHER CLAVERO SANCHEZ
